Deal Watch: Allergan Buys Kythera Anticipating Kybella Will Bolster Its Aesthetic Portfolio
Johnson & Johnson Innovation announces a spate of 17 deals, bringing its two-year total to more than 200 agreements. Celgene pays $82.5 million up front to partner with Kythera on a ROR gamma T program for cancer immunotherapy.
You may also be interested in...
In an effort to expand outreach to and interaction with innovation-rich communities, J&J is creating four new regional innovation centers to act as scouts, deal-makers and alliance managers in Shanghai, Boston, California and London.
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.
Roivant will form a new "vant" company to develop and commercialize Pfizer's TL1A inhibitor for ulcerative colitis.